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from P. falciparum Restricted by Multiple
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efficacious malaria vaccine have been undertaken. TheScott Southwood,2 Peggy A. Wentworth,2
finding that sterile protective immunity against malariaJohn Sidney,2 Robert W. Chesnut,2 Elissa Keogh,2
can be induced by immunization with radiation-attenu-Ettore Appella,3 Thomas B. Nutman,4 Altaf A. Lal,5
ated sporozoites of different Plasmodium spp. in mice,Daniel M. Gordon,6 Aggrey Oloo,7
monkeys, and humans (reviewed by Hoffman et al.,and Alessandro Sette2
1996) has focused much research on the preerythrocytic1Malaria Program
(sporozoite/liver) stage. A vaccine targeted at the pre-Naval Medical Research Institute
erythrocytic stage could prevent both sporozoites fromBethesda, Maryland 20889±5670
invading hepatocytes and liver-stage parasites from de-2Cytel Corporation
veloping to maturity. Such a vaccine would therefore3525 Johns Hopkins Court
prevent both clinical disease, which is manifested onlySan Diego, California 92121
during the erythrocytic stage, and the transmission of3National Cancer Institute
malaria, since no gametocytes would develop.National Institutes of Health
Considerable data implicateCD81 T cells in protection4Laboratory of Parasitic Diseases
against preerythrocytic-stage malaria. CD81 cytotoxicNational Institute of Allergy and Infectious
T lymphocytes (CTLs) can eliminate Plasmodium ber-Diseases
ghei± or Plasmodium yoelii±infected hepatocytes fromNational Institutes of Health
in vitro culture in a major histocompatibility complexBethesda, Maryland 20892
(MHC)±restricted and antigen-specific manner (Hoffman5Division of Parasitic Diseases
et al., 1989, 1990; Weiss et al., 1990). Furthermore, adop-Centers for Disease Control and Prevention
tive transfer of such CTLs can also protect against P.Atlanta, Georgia 30333
yoelii and P. berghei sporozoite-induced malaria in the6Department of Immunology
absence of other parasite-specific immune responsesWalter Reed Army Institute of Research
(Romero et al., 1989; Rodrigues et al., 1991; Weiss etWashington, DC 20307
al., 1992; Khusmith et al., 1994).7Kenya Medical Research Institute
Indirect evidence that CTLs may be important in pro-Kissian, Kenya
tective immunity against Plasmodium falciparum in hu-
mans has also accumulated. First, humans immunized
with irradiated sporozoites or naturally exposed to ma-
Summary
laria can generate a CTL response to the preerythro-
cytic-stage antigens, circumsporozoite protein (CSP),We recently described human leukocyte antigen (HLA)
sporozoite surface protein 2 (SSP2), liver-stage an-A2, A3 and B7 supertypes, characterized by largely
tigen-1 (LSA-1), and exported protein-1 (Exp-1) (Malik
overlapping peptide-binding specificities and repre-
et al., 1991; Doolan et al., 1991, 1993; Hill et al., 1992;
sented in a high percentage of different populations.
Sedegah et al., 1992; Aidoo et al., 1995; Wizel et al.,
Here, we identified 17 Plasmodium falciparum pep-
1995a, 1995b; Lalvani et al., 1996). Second, there is
tides capable of binding these supertypes and as- evidence that the polymorphism within the CSP may be
sessed antigenicity in both vaccinated and naturally the result of selection by CTLs of parasites that express
exposed populations. Positive cytotoxic T lymphocyte variant forms (McCutchan and Waters, 1990), since all
recall and cytokine (interferon-g and tumor necrosis variation is nonsynonymous at the nucleotide level, in-
factor a) responses were detected for all peptides; all dicative of selective pressure at the protein level; the
were recognized in the context of more than one HLA polymorphism primarily maps to identified CTL and T
class I molecule; and at least 12 of the 17 were recog- helper epitopes (Doolan et al., 1992); and CTL responses
nized in the context of all HLA alleles studied. These to some of the parasite variants do not cross-react (Hill
data validate the concept of HLA supertypes at the et al., 1992). Finally, the MHC class I human leukocyte
biological level, show that highly degenerate peptides antigen (HLA)±Bw53 has been associated with resis-
are almost always recognized as epitopes, and dem- tance to severe malaria in The Gambia, and CTLs to a
onstrate the feasibility of developing a universally ef- conserved epitope restricted by the HLA-Bw53 allele
fective vaccine by focusing on a limited number of have been identified on P. falciparum LSA-1 (Hill et al.,
peptide specificities. 1991, 1992). Since HLA-Bw53 is found in 15%±40% of
the population of sub-Saharan Africa but in less than
Introduction 1% of Caucasiansand Asians, these data suggest evolu-
tionary selection on the basis of protection against se-
An estimated 300±500 million new Plasmodium infec- vere malaria.
tions and 1.5±2.7 million deaths occur each year due to Based on these data, our group has undertaken the
malaria (World Health Organization, 1994). Fatal out- task of developing a vaccine designed to elicit CD81,
comes are not confined to first infections, and constant class I±restricted CTL responses. Specifically, we have
exposure is apparently a prerequisite for maintaining chosen an epitope-based approach because a multiepi-
tope vaccine would deal with the problems of geneticimmunity. Naturally acquired sterile immunity is rare if
Immunity
98
restriction and parasite polymorphism (Doolan and Hoff- of the high-affinity±binding peptides were derived from
CSP, 16 from SSP2, 10 from LSA-1, and 11 from Exp-1.man, 1997), and lipopeptide constructs have been
shown to be highly immunogenic for CTL induction in Previous studieshave indicated that an affinity threshold
of 500 nM or less is associated with immunogenicity inhumans (Vitiello et al., 1995) and efficacious in the pro-
phylactic vaccination mode in the murine lymphocytic the context of HLA class I molecules (Sette et al., 1994).
Accordingly, these 42 peptide±HLA combinations werechoriomeningitis virus model (van der Most et al., 1996).
The stringent specificity of the CD81 T cell±HLA inter- selected for further study.
actions and the high degree of genetic polymorphism
of HLA molecules could represent a major obstacle to Selection of Potential HLAA2-Supertype
the development of such epitope-based vaccines. How- P. falciparum Epitopes
ever, it has recently been shown that many different A total of 14 peptides of 50 tested bound HLA-A*0201
HLA alleles significantly overlap in their peptide-binding with good affinity (IC50 <500 nM) (data not shown). These
specificity (reviewed by Sidney et al., 1996a), leading to peptides were tested for immunogenicity using primary
the definition of HLA class I supertypes. Specifically, CTL cultures with PBMCs from at least four malaria-
an A2-binding supertype including at least HLA-A*0201, naive human donors and immunization of at least three
*0202, *0203, *0205, *0206, *6802, and *6901 has recently HLA-A*0201/Kb transgenic mice, as described pre-
been defined on the basis of a common peptide-binding viously (Wentworth et al., 1996). The induction of primary
motif (del Guercio et al., 1995). Peptide-binding motifs CTL responses in vitro with PBMCs from normal naive
associated with two other supertypes, the A3 supertype humans requires a brief treatment of the antigen-pres-
(including but not restricted to A*0301, A*1101, A*3101, enting cells with acidic buffer and subsequent neutral-
A*3301, A*3401, A*6601, A*6801, and A*7401) (Sidney ization in the presence of excess b2-microglobulin andet al., 1996b) and the B7 supertype (including B*0702±5, exogenous peptide (Wentworth et al.,1996). Byensuring
B*3501±3, B*5101±5, B*5301, B*5401, B*5501±2, that the majority of the HLA class I molecules are occu-
B*5601, B*6701, and B*7801) (Sidney et al., 1995, 1996c), pied by exogenous peptide, these steps are essential
have also been identified. Since each supertype is repre- for the induction of primary CTL responses. Such re-
sented in high frequencies (40%± 60%) in all major eth- sponses cannot be induced using methods developed
nicities, these data suggest that it should be possible for the induction of recall CTL responses (see below).
to represent approximately 80%±90% of the world pop- Here, a peptide was considered positive if yielding more
ulation by focusing on only three peptide-binding speci- than 2 LU30/106 cells (lytic units 30% per 106 cells, whereficities. one lytic unit corresponds to thenumber of effector cells
In this study we screened the sequences of P. falci- required to induce 30% 51Cr release from 10,000 target
parum preerythrocytic-stage antigens for the presence cells during a 6 hr assay) or 15% peptide-specific lysis,
of the A2-, A3- and B7 supertype binding motifs. Seven respectively, in at least two different transgenic mice
A2 supertype, eight A3 supertype, and two B7 supertype and two different primary CTL cultures. Of the 14 pep-
highly degenerate binding peptides were identified and tides tested, 5 scored positive both in primary in vitro
tested for their capacity to induce recall CTL and cyto- CTL responses and in HLA transgenic mice (data not
kine responses from peripheral blood mononuclear cells shown).
(PBMCs) of 6 volunteers immunized with irradiated spo- Next, these5 peptides were tested for theircapacity to
rozoites and 85 individuals naturally exposed to malaria. bind other common A2 supertype alleles (HLA-A*0202,
*0203,*0206, and *6802). The peptide SSP214±23, which
was immunogenic in primary human CTL cultures andResults
contains the SSP214±22 epitope (rather then SSP214±22 it-
self), was included in this analysis. In addition, we alsoIdentification of Conserved, High-Affinity
arbitrarily included the peptide Exp-183 (positive in theP. falciparum Peptides Containing Specific
murine CTL assays) and the peptide CSP394 (the fourth±HLA Class I Binding Motifs
highest-affinity A*0201 binder of the 50 A2-motif pep-Sequences of the target antigens were scanned for the
tides tested).presence of HLA-A*0201, A3, A11, and B7 binding motifs
Seven of seven peptides tested bound (IC50 <500 nM)as described in Experimental Procedures. Following
to two or more of the A2 supertype alleles tested (Tableconservancy determination and algorithm analysis to
1A). In particular, SSP214 bound all five molecules, whiletake into account the influence of secondary anchors,
Exp-180 and CSP394 bound four of the five alleles tested.274 peptide±HLA combinations of potential interest
In summary, the results presented in this section identi-were identified. Of these, 50 peptides contained the
fied a set of seven potential CTL epitopes, characterizedHLA-A*0201 binding motif, 203 the HLA-A3/A11 motif,
by degenerate binding capacity to multiple HLA-A2 su-and 26 the HLA-B7 motif. Five peptides contained both
pertype molecules.HLA-A*0201 and A3/A11 binding motifs. When the affin-
ity of peptide±HLA interaction was quantitated for each
of the peptide±HLA combinations, good-affinity binding Selection of Potential A3 Supertype and B7
Supertype P. falciparum Epitopes(half-maximal inhibitory concentration [IC50] <500 nM)
was detected in 42 of the 274 cases, 14 peptides binding Next, the binding capacity of A3 and B7 supertype P.
falciparum±derived peptides was examined. Of 203 pep-to HLA-A*0201, 25 to HLA-A3/A11, and 4 to HLA-B7
(data not shown). One peptide (Exp-12) bound with high tide±HLA combinations tested for binding, 25 peptides
bound with high affinity to either A3 or A11 (Table 1B).affinity to both HLA-A*0201 and HLA-A3/A11. Overall, 5
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Table 1. Potential Epitopes
(A) A2-Like Supertype Potential Epitopes
Binding (IC50, nM) Alleles
Protein First Position Sequence A*0201 A*0202 A*0203 A*0206 A*6802 Bound
SSP2 14 FLIFFDLFLV 12 10 5.9 11 333 5
Exp-1 80 VLAGLLGNV 19 24 0.67 31 606 4
CSP 394 GLIMVLSFL 22 19 3.6 74 4396 4
Exp-1 2 KILSVFFLA 5.0 172 3448 8.0 9524 3
Exp-1 83 GLLGNVSTV 24 1194 1.2 25 Ð 3
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Exp-1 91 VLLGGVGLVL 94 Ð 2500 420 Ð 2
CSP 7 ILSVSSFLFV 208 3583 19 587 2105 2
(B) A3-Like Supertype Potential Epitopes
Binding (IC50, nM) Alleles
Protein First Position Sequence A*0301 A*1101 A*3101 A*3301 A*6801 Bound
LSA-1 94 QTNFKSLLR 50 14 180 617 4.4 4
SSP2 523 LACAGLAYK 423 143 5294 64 32 4
CSP 344 VTCGNGIQVR 6875 11 15 64 444 4
Exp-1 10 ALFFIIFNK 9.2 2.2 720 1261 73 3
SSP2 522 LLACAGLAYK 22 73 692 1526 24 3
LSA-1 105 GVSENIFLK 151 5.0 2250 8286 10 3
LSA-1 59 HVLSHNSYEK 407 200 Ð Ð 114 3
LSA-1 11 FILVNLLIFH 733 1333 1957 397 154 2
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
LSA-1 49 RINEEKHEK 786 40 486 Ð Ð 2
Exp-1 2 KILSVFFLA 18 3.2 7826 5918 8889 2
LSA-1 1855 SLYDEHIKK 28 8.6 Ð Ð 615 2
LSA-1 60 VLSHNSYEK 79 19 Ð Ð 2857 2
Exp-1 28 GTGSGVSSK 126 40 Ð Ð 3478 2
LSA-1 111 FLKENKLNK 145 3750 Ð 2636 444 2
SSP2 522 LLACAGLAY 190 5000 Ð 6591 2500 1
CSP 85 KLRKPKHKK 250 Ð 2250 Ð Ð 1
SSP2 102 RLHSDASKNK 256 600 Ð Ð Ð 1
Exp-1 99 VLYNTEKGR 282 3158 8571 4203 1231 1
SSP2 100 IIRLHSDASK 324 Ð Ð Ð Ð 1
SSP2 521 ALLACAGLAY 355 779 5455 5088 Ð 1
LSA-1 16 LLIFHINGK 478 612 Ð Ð 167 1
LSA-1 1854 KSLYDEHIKK 1000 29 Ð Ð Ð 1
Exp-1 28 GTGSGVSSKK 1100 353 Ð Ð Ð 1
SSP2 120 SLLSTNLPY 1146 353 Ð Ð Ð 1
LSA-1 1854 KSLYDEHIK Ð 231 Ð Ð Ð 1
SSP2 307 RGDNFAVEK Ð 105 Ð Ð Ð 1
(C) B7-Like Supertype Potential Epitopes
Binding (IC50, nM) Alleles
Protein First Position Sequence B*0701 B*3501 B*5101 B*5301 B*5401 Bound
Pfs16 77 MPLETQLAI 86 31 8.1 1.5 1.7 5
SSP2 539 TPYAGEPAPF 31 14 15 158 Ð 4
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
SSP2 305 RPRGDNFAV 5.0 Ð Ð Ð 526 1
SSP2 206 HPSDGKCNL 275 Ð Ð 3321 Ð 1
SSP2 303 QPRPRGDNF 500 Ð Ð Ð Ð 1
Dash indicates binding affinity >10,000 nM.
These peptides were further tested for their capacity to Likewise, 4 of 24 peptides tested for binding to HLA-
B7 bound with high affinity. Of these, 1 peptide (SSP2539)bind other common members of the A3 supertype (A31,
A33, and A*6801). Seven of them exhibited degenerate bound four of five B7 supertype alleles (Table 1C). The
previously reported HLA-B±restricted peptide Pfs1677binding to three or more of the five alleles and were
selected for further study. We also arbitrarily considered (Hill et al., 1992) was also tested and found to bind five
of the five alleles (Table 1C).for further study the LSA-111 peptide, which bound
strongly to A33 and A*6801 and weakly to A3 and A11 In summary, the data presented here identified a total
of eight HLA-A3 and two HLA-B7 peptides that bound(Table 1B).
Immunity
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SSP2539 were detected in 85.7% (6/7) assays; 100% re-
producibility (2/2 assays) was observed for both pep-
tides in an HLA-B571 individual. The overall reproduc-
ibility of response was 42.9% (18/42 assays) for the A2
supertype peptides, 67.2% (43/64 assays) for the A3
supertype peptides, and 85.7% (12/14 assays) for the
B7 supertype epitopes.
A summary of the frequency and magnitude of the
CTL responses detected in the sporozoite-immunized
volunteers is presented in Table 2. As defined in Experi-
mental Procedures and in previous studies (Aidoo et al.,
1995; Wizel et al., 1995a, 1995b; Lalvani et al., 1996), a
CTL culture was considered positive if yielding greater
than 10% peptide-specific lysis (percentage peptide ly-
sis 2 percentagecontrol lysis). According to this criteria,
Figure 1. Induction of Peptide-Specific, MHC-Restricted, Sporozo- all HLA-A2, HLA-A3, and HLA-B7 degenerate, high-bind-
ite-Induced Recall CTL Response to A2, A3, and B7 Supertype Pep- ing peptides tested were recognized as CTL epitopes
tides by PBMCs derived from HLA-matched sporozoite-
PBMCs from a volunteer immunized with irradiated sporozoites who immunized volunteers.
expressed the HLA A*0201, A33, and B7 antigens were stimulated
Specifically, it was established that all of the A2-bind-in vitro with each of the peptides as described in Experimental
ing peptides were recognized in association with HLA-Procedures. Cultures were assessed for cytotoxicity at an ef-
A*0201 and that all of the A3-binding peptides werefector:target ratio of 30:1 against PHA blast targets: either appro-
priate peptide-sensitized autologous PHA blasts (MHC 1 peptide), recognized in association with both A3 and A33, while
unsensitized autologous PHA blasts (MHC 2 peptide), or appro- the B7-binding peptides were presented in association
priate peptide-sensitized MHC-mismatched PHA blasts (non- with B7, B35, and B57 (Table 2). None of sporozoite-
MHC 1 peptide).
immunized volunteers expressed the alleles HLA-
A*0202, A*0205, A11, A31, A68, B51, or B53, and antige-
multiple members of the respective supertype with high nicity of the peptide panel in the context of these alleles
affinity. therefore could not be addressed.
The fraction of individuals responding to each peptide
Antigenicity of HLA Supertype Degenerate varied between 33.3% (for one of three A31 individuals
Binding Peptides for Irradiated tested for reactivity to the peptide Exp-110) and 100%
Sporozoite±Immunized Individuals (for five of seven A2 peptides, three of eight A3 peptides,
In the next series of experiments, the HLA class I degen- and two of two B7 peptides) (Table 2). The magnitude
erate binding peptides selected as described in the pre- of responses also varied, with average specific lysis
vious sections were tested for their ability to elicit in vitro values in the 15%±39% range for A2 supertype±
recall responses from frozen PBMCs of six volunteers restricted responses, in the 16%±55% range for A3 su-
immunized with irradiated sporozoites. pertype peptides, and 15%±27% in the case of B7 su-
Representative data, derived from one donor who ex- pertype epitopes (Table 2).
pressed the HLA-A*0201, A33, and B7 alleles, are shown In summary, these data demonstrate that all of the
in Figure 1. The recall CTL responses elicited by the P. epitopes predicted on the basis of the in vitro analysis
falciparum peptides were antigen specific since no lysis are indeed processed and presented in vivo and recog-
of MHC-matched target cells was detected in the ab- nized following immunization with irradiated sporozo-
sence of peptide. Furthermore, these responses were ites. Furthermore, they also show that a T cell repertoire
MHC restricted since no specific lysis was detected in susceptible of being expanded as a result of deliberate
the presence of appropriate peptide in association with immunization exists for each of them.
MHC-mismatched target cells. These responses were
indeed induced by exposure to P. falciparum since no Antigenicity of Degenerate Peptides for
specific CTL responses could be generated from pre- Recall CTLs from Naturally
bleeds of the same volunteers collected before sporozo- Exposed Individuals
ite immunization (data not shown). In the next series of experiments, we examined whether
Finally, the detected CTL activity was reproducible, specific CTL responses could also be recalled from fro-
since most donors were tested multiple times and re- zen PBMCs of semi-immune or nonimmune individuals
sponses were detected inup to87.5% of assays. Specif- naturally exposed to malaria, with an estimated mean
ically, the reproducibility of CTL responses for the A2 of 22 bites per 28 day period (Beier et al., 1994; McElroy
supertype peptides ranged from 16.7% (1/6 assays) with et al., 1994).
CSP7 and SSP214 to 66.7% (4/6 assays) with CSP394 and Initially, a total of 197 Kenyan individuals were HLA
Exp-183. For the A3 supertype epitopes, reproducibility typed. Of these, 39.0% expressed class I alleles of the
ranged from 50.0% (4/8 assays) with Exp-110 to 87.5% HLA-A2 supertype (subtyped as A*0201, 55.6%; A*0202,
(7/8 assays) with CSP344; activity was detected in 100% 30.6%; and A*0205, 13.9%); 23.4% expressed HLA-A3
(5/5) of assays with peptides LSA-194, LSA-111, and supertype antigens (A3, 7.1%; A31, 10.2%; A33, 6.1%;
CSP344 when tested in HLA-A31 individuals. For the B7 and A*6801, 11.7%); and 34.5% expressed HLA-B7 su-
pertype molecules (B7, 8.6%; B35, 7.1%; B51, 4.6%;supertype peptides, responses to both Pfs1677 and
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and B53, 16.2%). Twenty-nine individuals were HLA-A69 context of three of four alleles (A3, A33, and A68, or A3,
A31 and A33, respectively), peptide LSA-1105 in two ofpositive but were not tested for recall CTL responses
because of unavailability of an assay to discriminate three alleles (A3 and A33), and SSP2523 in two of four
alleles (A3 and A33). Similarly, the B7-binding peptidesbetween different subtypes of this allele. The overall
fraction of individuals expressing at least one molecule Pfs1677 and SSP2539 were recognized as CTL epitopes
in the context of three of the five B7 supertype allelesfrom any of the three supertypes was 84.8%.
A representative subset of 53 naturally exposed indi- (B7, B35, and B57).
viduals were tested for recall CTL responses as de-
scribed above. Of these, 18 subjects expressed alleles
Induction of Cytokine Responses by P. falciparumincluded in the A2 superfamily; 24 were members of the
Degenerate CTL EpitopesA3 supertype; and 14 were in the B7 supertype. Overall,
In addition to investigating whether the peptides underA2, A3, and B7 supertype±binding peptides were tested
study could be recognized as CTL epitopes, we soughtfor reactivity in a total of 47, 63, and 24 assays, respec-
tomeasure the ability of such peptides to induce specifictively. The frequency and magnitude of the CTL re-
cytokine responses. In particular, we studied interferon-sponses is summarized in Table 3. Recall CTL responses
g (IFNg) and tumor necrosis factor a (TNFa), which have(percentage specific lysis .10%) were detected for one
been implicated in protective immunity against malariaof seven A2-binding peptides, five of eight A3-binding
(Ferreira et al., 1986; Mellouk et al., 1987, 1991; Schofieldpeptides, and two of two B7-binding peptides. Clear
et al., 1987a, 1987b; Nussler et al., 1991). Frozen PBMCsresponses were detected in association with HLA-
from all six irradiated sporozoite±immunized volunteersA*0201, A31, A33, A68, B7, and B35 alleles. Significant
as well as fresh PBMCs from a subset of 85 naturallyCTL responses were not detected in individuals ex-
exposed individuals, including the 53 tested for recallpressing the HLA-A*0202, A*0205, A3, or B53 alleles.
CTL responses, were studied.The frequency of individuals responding varied be-
Significant peptide-induced responses for IFNg and/tween 0% (for six of the seven A2 and three of the eight
or TNFa were observed for all HLA-A2, A3, and B7 de-A3 supertype peptides) and 66.7% (two of three A311
generate, high-binding peptides tested (see Experimen-individuals tested for reactivity to the peptide SSP2522)
tal Procedures for criteria and definition of significantor 100% (one of one A681 individuals responding to
responses). Figure 2 shows representative data illustrat-peptides CSP344 or LSA-111) (Table 3). The magnitude of
ing peptide-specific induction of IFNg from naturally ex-response (average specific lysis) was 14% for the A2
posed individuals expressing class I molecules of thesupertype peptides and ranged from 13% to 32% for
HLA-A3 supertype and each of the eight peptides testedthe A3 supertype peptides and 14% to 20% for the B7
plus a control peptide (Exp-183). A summary of the datasupertype peptides. In general, both the frequency and
from naturally exposed individuals, incorporating allmagnitude of responses were lower in the PBMCs of
peptide-specific responses, is presented in Table 4.naturally exposed individuals (Table3) than in volunteers
Specifically, the fraction of individuals responding var-immunized with irradiated sporozoites (Table 2). This
ied between 6% (2 of 36 A2 supertype donors testedfinding is consistent with responses detected in other
for IFNg in response to peptide Exp-12) and 54% (23 offield studies (Doolan et al., 1991, 1993; Hill et al., 1992;
43 A3 supertype donors tested for TNFa responding toSedegah et al., 1992; Aidoo et al., 1995; Lalvani et al.,
peptide LSA-111). The magnitude of responses varied,1996).
with the most vigorous average responses observed in
the case of the A2 supertype peptide Exp-191 for IFNg
(860 pg/ml; range 420±1123 pg/ml) and the A2 supertypeDegeneracy of Recall CTL Responses
to A2, A3, and B7 Supertype Peptides peptide SSP214 for TNFa (113 pg/ml; range 3±924 pg/
ml). Overall, significant TNFa responses (p , 0.05) wereNext, the recall CTL data from both sporozoite-immu-
nized and naturally exposed individuals (Tables 2 and detected for seven of seven A2, seven of eight A3, and
two of two B7 supertype peptides (statistical data not3) were examined in terms of degeneracy of CTL re-
sponses. Specifically, we examined whether each CTL shown). Significant IFNg responses (p , 0.05) were de-
tected for three of seven A2 supertype epitopes, five ofepitope was recognized in the context of multiple HLA
class I molecules derived from the same supertype. eight A3 supertype peptides, and one of two B7 su-
pertype epitopes. For PBMC cultures from individualsDegenerate antigenicity could not be examined at the
CTL level for the A2 supertype peptides because the who did not express HLA-A2, the A2 supertype peptide
Exp-183 was used as the control peptide; in HLA-A2±irradiated sporozoite±immunized volunteers expressed
only HLA-A*0201 and the CTL reactivity of the naturally positive cultures, the A3 supertype peptide CSP344 was
used. Occasional responses were also noted in someexposed individuals with these peptides was poor.
By contrast, degeneracy of recall CTL responses to all of the ªsupertype-mismatchedº control cultures. Never-
theless, the frequency and magnitude of observed re-A3-binding and B7-binding peptides was clearly demon-
strated. The A3 supertype peptide CSP344 was recog- sponses to the control peptides were markedly lower
than those observed to the supertype-matched pep-nized in the context of four of the four A3 supertype
alleles tested (A3, A31, A33, and A68), peptides Exp-110 tides. Responses may be attributed to the fact that all
peptides were preselected for degenerate binding toand LSA-111 in the context of three of three alleles (A3,
A31, and A33,or A3, A33, A68, respectively), and peptide three or more class I alleles within a particular HLA
supertype. Therefore, it is possible that these peptidesLSA-159 in the context of two of two alleles (A3 and A33).
Peptides LSA-194 and SSP2522 were recognized in the may in fact bind to other alleles expressed in the Kenyan
P. falciparum HLA Degenerate CTL Epitopes
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and B57). Peptide Pfs1677, the other B7 supertype pep-
tide, was recognized in association with four of the five
alleles (B7, B35, B53 and B57).
Phenotype of Responding T Cells
The nonamer and decamer peptides in this study were
selected on the basis of ability to bind to HLA class I
alleles. Typically, class I binding peptides have a pre-
ferred size of 9 6 1 amino acids, while peptides that
bound to class II molecules range in size between 12
and 24 residues (Chicz and Urban, 1994), although pep-
tides as short as seven (Rajadhyaksha and Thanavala,
1995) or eight (Suhrbier et al., 1991; Franco et al., 1994)
amino acids may bind. Here, we assessed the ability
of the 17 peptides to stimulate a lymphoproliferative
response or stimulate release of interleukin-5 (IL-5), a
Figure 2. Induction of IFNg by each A3 Supertype Peptide and Non- lymphokine usually associated with class II responses.
A3 Control Peptide Little or no proliferation and no significant IL-5 release
PBMCs from individuals naturally exposed to malaria who ex- were observed in 691 and 702 independent cultures,
pressed any of the A3 supertype alleles were stimulated in vitro
respectively (data not shown). In addition, the activatedwith each of the A3 binding peptides as described in Experimental
T cell populations responsible for cytokine secretionProcedures. Supernatants were assessed for IFNg production using
were examined for expression of CD31,CD41, and CD81a standard enzyme-linked immunosorbent assay. Concentrations
were calculated by interpolation from standard curves based on cell surface markers. Activated T cells were almost ex-
recombinant cytokine dilutions. Any background level of cytokine clusively CD81, with only a few CD41 T cells observed
production in cultures not stimulated with peptide was subtracted in only a small proportion of cultures (data not shown).
from peptide-induced responses.
In summary, the data were consistent with a CD81 T
cell phenotype for the activated T cells.
Correlation between CTL and Cytokine Responsesstudy population that were not tested for in vitro binding
Next, we examined the data for correlations betweencapacity.
CTL activity and cytokine responses. In the case of irra-For the irradiated sporozoite±immunized volunteers,
diated sporozoite volunteers, 92.3% of the IFNg re-significant TNFa responses (p , 0.05) were detected
sponders and 83.9% of the TNFa responders for a givenfor all A2 and B7 and seven of eight (not LSA-1105) A3
peptide were also positive for recall CTL responses. Insupertype peptides (8 pg/ml; range 2±40 pg/ml). Signifi-
contrast, 0% (IFNg) and 3.4% (TNFa) of the naturallycant IFNg responses (p , 0.05) were detected for six of
exposed individuals who responded to a specific pep-seven A2 (not CSP394), four of eight A3 (Exp-110, LSA-
tide were able to mount similar recall CTL responses1105, LSA-111, and LSA-159), and one of two B7 (Pfs1677)
to that peptide. From a different perspective, of thosesupertype peptides (369 pg/ml; range 40±711 pg/ml)
individuals in whom a peptide-specific recall CTL re-(data not shown). There were no detectable TNFa or
sponse was detected to that peptide, TNFa and IFNgIFNg responses to control peptides.
were detected in 81.3% and 37.5% of vaccinee cultures,
respectively, as compared to 5.3% and 0% of cultures
from naturally exposed individuals.Degeneracy of Cytokine Responses to HLA
A2, A3, and B7 Supertype Peptides
We next examined the data from both sporozoite-immu- Summary of Frequency of Responses against
nized and naturallyexposed donors todetermine wheth- Degenerate HLA Supertype Epitopes
er each epitope could induce cytokines in the context A summary of CTL, TNFa, and IFNg responses for each
of multiple HLA class I molecules derived from the same individual peptide was compiled (Figure 3). Significant
supertype (data not shown). Degeneracy of cytokine CTL, TNFa and IFNg responses were detected for all
responses to all peptides, in particular the A3-binding peptides in one or more populations. Specifically, in
and B7-binding peptides, was readily apparent. Three irradiated sporozoite±immunized volunteers (Figure 3A),
of the seven A2 supertype peptides (CSP394, Exp-183, significant CTL responses were obtained to all 17 pep-
and Exp-12), were recognized in the context of three of tides; significant TNFa responses to all A2- and B7- and
the three A2 supertype alleles studied (A*0201, A*0202, seven of eight A3-binding peptides; and significant IFNg
and A*0205) and peptides Exp-180, CSP7, Exp-191, and responses to six of seven A2, four of eight A3, and
SSP214 were recognized in the context of two of the one of two B7 supertype epitopes. In naturally exposed
three alleles (A*0201 and A*0202). More striking, eight individuals (Figure 3B), significant CTL responses were
of the eight A3 supertype peptides were recognized in detected to one of seven A2, five of eight A3, and two
the context of all four A3 supertype alleles studied (A3, of two B7 supertype peptides; significant TNFa re-
A31, A33, and A68), and one of the two B7 supertype sponses to all A2-, A3-, and B7-binding peptides; and
epitopes (SSP2539) was recognized in association with significant IFNg responses to three of seven A2, five of
five of the five B7 supertype alleles (B7, B35, B51, B53, eight A3, and two of two B7 supertype epitopes.
The frequency of peptide-specific CTL responses in
P. falciparum HLA Degenerate CTL Epitopes
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the A2, A3, or B7 supertype peptides, respectively. The
range of A2-, A3- or B7-restricted TNFa responses was
11.4%±31.4%, 18.6%±53.5%, or 9.8%±12.2%, and the
range of IFNg responses was 5.6%±11.1%, 2.2%±
17.8%, or 6.7%±11.1% (Figure 3B).
The overall frequencies of CTL, TNFa, and IFNg re-
sponses for each supertype are presented in Table 5.
In irradiated sporozoite volunteers, there was a markedly
high prevalence of CTL responsiveness (6 of 6 of individ-
uals responding in 73 of 120 [60.8%] of assays) and a
high prevalence of cytokines (6 of 6 of individuals induc-
ing either TNFa or IFNg in a total of 34 of 38 [89.5%] of
assays). In contrast, in naturally exposed individuals,
the prevalence of CTL responsiveness was lower (10 of
53 of individuals responding in 19 of 134 [14.2%] of
assays), as was the prevalence of cytokines (60 of 85
of individuals inducing either TNFa or IFNg in a total of
217 of 702 [30.9%] of assays).
In both populations, an overall hierarchy of antigenic-
ity was apparent, with the B7 supertype peptides being
the most immunogenic, followed by the A3 supertype
peptides, and finally the A2 supertype peptides.
In summary, the data indicate that in an immune popu-
lation with a high prevalence of CTL responsiveness (73
of 120 assays [61%]), IFNg and/or TNFa are induced in
almost all (34 of 38 assays [89.5%]) cases of specific
peptide stimulation, and CTL response is almost always
associated with induction of IFNg and TNFa. However,
in a semi-immune or nonimmune population, the preva-
lence of CTL responsiveness is low (19 of 134 assays
[14.2%]); the induction of cytokines is less frequent
(30.9% of cases); and there is no significant association
between CTL and cytokine responses (data not shown).
Figure 3. Summary of CTL, TNFa, and IFNg Responses for each
Peptide Summary of Breadth of Responses against
(A) Summary of frequency of CTL, TNFa, and IFNg responses in Degenerate HLA Supertype Epitopes
individuals immunized with irradiated sporozoites to each of the A2, A summary of the degeneracy of each of the 17 peptides
A3, and B7 supertype peptides. PBMCs from volunteers immunized
in terms of binding capacity and antigenicity is pre-with irradiated sporozoites who expressed the appropriate alleles
sented in Table 6. Eight of eight A3 supertype peptideswere stimulated in vitro with each of the peptides and tested for
that exhibited highly degenerate binding capacity inrecall CTL, at an effector:target ratio of 30:1, and cytokine responses
as described in Experimental Procedures. The number of individuals vitro also demonstrated highly degenerate antigenicity
tested for each peptide varied, depending on the assay. For CTL at the level of both CTL and cytokine responses. In
assays: A2, n 5 6; A3, n 5 8; and B7, n 5 7. For TNFa and IFNg particular, CSP344 bound to four of five alleles of the A3
assays: A2, n 5 2; A3, n 5 2; and B7, n 5 3. supertype and induced both CTL and cytokine re-
(B) Summary of frequency of CTL, TNFa, and IFNg responses in
sponses in association with four of four alleles studied.individuals naturally exposed to malaria to each of the A2, A3, and
Peptides Exp-110 and LSA-111 also induced a CTL re-B7 supertype peptides. PBMCs from volunteers naturally exposed
to malaria who expressed the appropriate alleles were stimulated sponse in three of three alleles tested and a cytokine
in vitro with each of the peptides and tested for recall CTLs, at an response in four of four alleles, even though high-affinity
effector:target ratio of 30:1, and cytokine responses as described binding was detected to only three of five and two of five
in Experimental Procedures. The number of individuals tested for
alleles, respectively. These data suggest that, providedeach peptide varied, depending on the assay. For CTL assays: A2,
that a peptide can bind to a specific HLA molecule,n 5 3±11; A3, n 5 2±12; and B7, n 5 10±14. For TNFa assays, A2,
subsequent antigenicity and immunogenicity may notn 5 35; A3, n 5 43; and B7, n 5 41. For IFNg assays, A2, n 5 36;
directly correlate with the affinity of binding per se.A3, n 5 45; and B7, n 5 45.
The B7 supertype peptides showed a similar pattern
of highly degenerate antigenicity for both CTL and cyto-
irradiated sporozoite±immunized volunteers was 50%± kines (Table6). In contrast, a pattern of lower antigenicity
100%, 33.3%±100%, or 100%, for the A2, A3, or B7 was noted for the A2 supertype peptides, especially in
supertype peptides, respectively. The range of A2-, A3- terms of recall CTL responses (Table 6).
or B7-restricted TNFa responses was 50%±100%, 0%± In summary, all peptides were recognized in the con-
100%, or 100%, and the range of IFNg responses was text of more than one HLA class I molecule, and three of
0%±100%, 0%±50%, or 0%±33.3% (Figure 3A). In natu- seven A2, eight of eight A3, and one of two B7 supertype
rally exposed individuals, the frequency of CTL re- peptides were recognized in the context of all HLA al-
leles studied.sponses was 0%±9.1%, 0%±41.7%, or 28.6%±30% for
P. falciparum HLA Degenerate CTL Epitopes
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Table 6. Summary of Peptide Degeneracy at the Level of HLA
Binding and CTL and Cytokine (IFNg and/or TNFa) Responses
Number of Alleles Recognized
HLA CTL Cytokine
Supertype Peptide Binding Responses Responses
A2 CSP394 4/5 1/3 3/3
Exp-183 3/5 1/1 3/3
Exp-180 4/5 1/2 2/3
Exp-12 3/5 1/2 3/3
CSP7 2/5 1/2 2/3
Exp-191 2/5 1/2 2/3
SSP214 5/5 1/3 2/3
A3 Exp-110 3/5 3/3 4/4
LSA-1105 3/5 2/3 4/4
LSA-194 4/5 3/4 4/4
SSP2523 4/5 2/4 4/4
CSP344 4/5 4/4 4/4
LSA-111 2/5 3/3 4/4
LSA-159 3/5 2/2 4/4
SSP2522 3/5 3/4 4/4
B7 Pfs1677 5/5 3/5 4/5
SSP2539 4/5 3/5 5/5
Discussion
In this study, we have used a combination of immuno-
chemical and cellular analyses based on HLA-specific
peptide-binding motifs to identify 17 degenerate CD81
T cell epitopes from a number of P. falciparum preeryth-
rocytic-stage antigens that are restricted by A2 su-
pertype, A3 supertype, and B7 supertype alleles. Pep-
tide sequences from the P. falciparum antigens CSP,
SSP2, LSA-1, and Exp-1 conforming to specific class I
binding motifs were synthesized. Peptides that bound
with good (IC50 <500 nM) affinity to A*0201, A*0302,
A*1101, or B*0702 molecules were tested for their ca-
pacity to bind multiple molecules of the corresponding
supertype. Seventeen of 42 peptides tested exhibited
degenerate binding and were subsequently tested for
their capacity to elicit recall CTL and cytokine responses
from PBMCs of volunteers either immunized with irradi-
ated sporozoites or naturally exposed to malaria.Seven-
teen of seventeen peptides tested were antigenic; all of
them were recognized in the context of more than one
HLA allele; and at least 12 of them (71%) were recog-
nized in the context of all HLA alleles studied.
The data presented here have several important impli-
cations. First, in terms of population coverage, the data
support, in the case of a parasitic disease of medical
importance such as malaria, the feasibility of a subunit
vaccine comprising three degenerate peptide specificit-
ies. Of the 197 naturally exposed Kenyan individuals
who were HLA typed, 39.0% expressed class I alleles
classified as HLA-A2±like, 23.4% were HLA-A3±like, and
34.5% were HLA-B7±like. The overall fraction of individ-
uals expressing at least one molecule from any of the
three supertypes was 84.8%. These data are consistent
with our previous predictions (Sidney et al., 1996a). Fur-
ther studies will be required to examine whether these
three supertypes will allow adequate population cover-
age in the majority of all racial and ethnic populations.
Second, these data illustrate that degenerate HLA
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binding capacity appears to be relatively frequent.
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Thirty-six percent (5 of 14) of peptides tested that bound from the hepatitis B virus (HBV) (Bertoni et al., unpub-
lished data).HLA-A*0201 with good affinity and were immunogenic
The data presented here also have implications forin vitro, 28% (7 of 25) of peptides that bound to either
our understanding of the interplay between PlasmodiumA3 or A11, and 40% (2 of 5) of peptides that bound to
spp. infection and immunity to malaria. Even thoughHLA-B7 exhibited degenerate binding to three or more
antigen-specific CTL can eliminate infected hepato-of the respective A2 supertype, A3 supertype, or B7
cytes from in vitro culture (Hoffman et al., 1989, 1990),supertype alleles tested. In fact, one of the A2-binding
the level of cytotoxicity observed in naturally exposedpeptides and one of the B7-binding peptides bound to
individuals is clearly not sufficient to eliminate all in-all five of the alleles, and two A2-binding, three A3-
fected hepatocytes in vivo and thus protect against ma-binding, and one B7-binding peptides bound to four of
laria. Accordingly, optimal vaccine design may be re-the five alleles. These data suggest that peptides capa-
quired to boost T cell or CTL precursor cells andble of degenerate binding capacity are relatively fre-
enhance T cell responses. The data here demonstratequent and should therefore be identifiable in most anti-
that it is possible to induce malaria-specific recall CTLgenic systems.
responses of high magnitude (up to 57% specific lysis)The finding that each of the 17 peptides identified was
as well as high frequency. Peptide-specific CTL re-antigenic for both recall CTL and cytokine responses
sponses were detected in a total of 100% (6 of 6) ofis especially remarkable. Malaria peptide-specific CTLs
individuals in 60.8% (73 of 120) of assays using PBMCswere first identified in 1991 (Doolan et al., 1991; Malik
from sporozoite-immunized volunteers, but in onlyet al., 1991), and CTLs restricted by defined HLA alleles
18.9% (10 of 53) of individuals in 14.2% (19 of 134) ofwere described in 1992 (Hill et al., 1992). Since then, a
assays in which effector cells were derived from natu-total of 19 HLA restricted CTL epitopes (reviewed by
rally exposed individuals. This pattern has been reportedDoolan et al., 1996b) have been reported as a result of
previously (Malik et al., 1991; Wizel et al., 1995a, 1995b)extensive research by three laboratories over a period
and may be a reflection of the high antigenic loadof 6 years. Only 13 of these 19 epitopes are minimal. In
achieved in the case of irradiated sporozoite immuni-the present study, we have identified 17 nonamer or
zation.decamer epitopes derived from five P. falciparum pre-
Although it is well established that antigen-specificerythrocytic-stage antigens, underscoring the power of
CD81 T cells can completely protect against malaria in
our approach.
the absence of other parasite-specific immune re-
It should be noted that in the present study, peptides
sponses (reviewed by Hoffman et al., 1996), a specific
were preselected for high-affinity binding to selected
marker of protective immunity has not yet been identi-
class I HLA molecules, and A2-binding peptides were
fied. Several reports in both rodent and human systems
also screened in HLA-A*0201 transgenic mice. More-
suggest that the induction of CTLs against Plasmodium
over, peptides were also preselected for good binding spp. proteins does not necessarily correlate with protec-
to three or more alleles of the respective HLA superfam- tion of the host. We have previously proposed (Doolan
ily. In fact, only a relatively small proportion of peptides et al., 1996a; Hoffman et al., 1996) that the CD81 T cell
fulfill such stringent selection criteria. Here, only 7 of 50 activated by interacting with the MHC±peptide complex
peptides tested for binding to HLA-A*0201, 8 of 203 on the surface of the infected hepatocyte may secrete
peptides tested for binding to HLA-A3/A11, and 2 of 24 IFNg, which in turn may induce the infected hepatocyte
peptides tested for binding to HLA-B7 were selected to produce nitric oxide, rendering the parasite noninfec-
for antigenicity studies. All of thesepeptides were recog- tious. Accordingly, in this investigation, we studied the
nized as epitopes for both CTL and cytokine responses. ability of the 17 peptides to induce specific responses
In contrast, in studies utilizing nonquantitative assays of selected cytokines implicated in protective immunity
and the antigens CSP, SSP2, LSA-1, Exp-1, and Pfs16, (specifically, IFNg and TNFa). For all peptides tested,
1 of 60 HLA-B53, 3 of 10 HLA-B35, 1 of 60 HLA-B7, 3 the capacity to recall specific responses of one or more
of 23 peptides HLA-B8, 1 of 62 HLA-B17, and 3 of 61 of these cytokines was demonstrated. Moreover, with
HLA-A2 binding peptides were identified as CTL epi- regard to recall CTL responses, the prevalence of cyto-
topes (overall 12 of 276; 4.4%) (Hill et al., 1992; Aidoo kine responsiveness was much higher in an immune
et al., 1995). population than in a semi-immune or nonimmune popu-
The high frequency of antigenicity detected in the lation.
case of HLA degenerate peptides might be explained, The epitopes identified here may be incorporated in
at least in part, by previous quantitative analysis of the a vaccine designed to protect humans against P. falci-
peptide preferences of the transporters associated with parum malaria via a CD81 T cell±mediated immune re-
antigen processing (TAP) (van Endert et al., 1995; Sidney sponse. Such a vaccine may be composed of multiple
et al., 1996a). Specifically, it has been noted that highly constructs molecule made up of three distinct structural
degenerate peptides conform to specific ªsupermotifs,º units: CD81 T cell epitopes, CD41 T helper epitopes,
and that ªHLA supermotifsº are preferentially trans- and lipid. Previous studies (Vitiello et al., 1995) have
ported by TAP molecules. In other words, the high anti- demonstrated that this type of lipopeptide construct
genicity of supertype peptides illustrates the biological is efficacious in inducing a CTL response in humans.
consequences of similar (and perhaps coordinate) pep- Alternatively, CD81 and CD41 epitopes may be encoded
tide specificities of TAP and HLA molecules (Sidney et in suitable DNA vaccines or recombinant infectious
al., 1996a). In this respect, it is worth noting that similarly, agents. In addition to circumventing the problem of ge-
highly antigenic HLA degenerate, class I peptides have netic restriction of the immune response, such a multiva-
lent vaccine incorporating a wide repertoire of specifici-been observed recently in the case of epitopes derived
P. falciparum HLA Degenerate CTL Epitopes
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Radiolabeled probe and standard control peptides used in theties at the epitope level may prevent parasite escape
different assays are as follows. A F6→Y analog of the HBV corefrom immune recognition because of strain variability
18±27 peptide (sequence FLPSDYFPSV) (Ruppert et al., 1993) wasand epitope mutation. Furthermore, a multivalent re-
used as the radiolabeled probe for the A*0201, A*0202, A*0203, and
sponse is also likely to be more vigorous and efficacious A*0206 assays. A C4→A analog of the HBV pol 646±654 peptide
in eliciting a protective immune response. (sequence FTQAGYPAL) was used as the radiolabeled probe for the
A*6802 assay. Radiolabeled probes used for A3 supertype alleles,In conclusion, thedata presented validate the concept
A3CON1 peptide (sequence KVFPYALINK), and HBV core 141±151of class I HLA supertypes at the biological level in the
peptide (sequence STLPETYVVRR), and B7 supertype alleles,context of a disease of worldwide importance. Further-
B35CON2 peptide (sequence FPFKYAAAF), and A*0201 signal se-more, they reveal a striking association between HLA
quence L7→Y (APRTLVYLL), have been described elsewhere (Sidney
degenerate binding capacity and antigenicity for class et al., 1996b, 1996c).
I±restricted responses. Finally, the results support the
feasibility of a subunit malaria vaccine comprising as Peptide Synthesis
Peptides were either synthesized at Cytel Corporation (San Diego,few as three peptide-binding specificities that would be
CA), as previously described (Ruppert et al., 1993) or, for largepotentially immunogenic in the majority of all racial and
epitope libraries, purchased as crude material from Chiron Mimo-ethnic populations.
topes (Chiron Corporation, Clayton, Victoria, Australia). Peptides
synthesized at Cytel were purified to greater than 95% homogeneity
Experimental Procedures by reverse-phase HPLC. The purity of these synthetic peptides was
determined on an analytical reverse-phase column andtheir compo-
Cell Culture sition ascertained by amino acid analysis and/or mass spectrometry
The following Epstein-Barr virus± transformed cell lines were used analysis.
as sources of class I molecules: JY (A*0201), FUN (A*0203), CLA
(A*0206), AMAI (A*6802, B*5301), GM3107 (A*0301, B*0701), BVR Sequence Analysis
(A*1101), SPACH (A*3101), LWAGS (A*3301), KAS116 (B*5101), and Complete sequences of the P. falciparum antigens CSP, SSP2,
KT3 (B*5401). The mouse B cell lymphoma P815 transfected with LSA-1, and Exp-1 were searched for the presence of conserved 9±
A*0202 was also utilized. C1R transfectants were used for the isola- or 10±amino acid sequences containing extended HLA-A*0201, A3,
tion of A*6801 and B*3501. These C1R transfectants were character- A11, or B7 binding motifs (Ruppert et al., 1993; Kubo et al., 1994;
ized by W. Storkus (Storkus et al., 1993) and Dr. M. Takaguchi (Ooba Sidney et al., 1995, 1996c). Multiple isolates were available for two
et al., 1989), respectively. of the aforementioned antigens. Motif-containing peptides that ex-
The HLA-A*0201±expressing cell line 771.221 was derived by hibited 100% conservancy in 80% or more of different isolates were
transfecting the human class I null mutant B cell line, 721.221 (Shim- considered for synthesis. These peptides were subjected to a cus-
izu and DeMars, 1989) with the HLA-A*0201 heavy chain gene as tomized computer algorithm analysis program that takes into ac-
described previously (Celis et al., 1994). EHM, BVR, and JY cells count secondary effects of residues at each nonanchor position of
are homozygous human Epstein-Barr virus±transformed B cell lines the peptide (Ruppert et al., 1993; Sidney et al., 1996a; Sidney et al.,
expressing A3, A11, and B7 respectively. K562, a natural killer cell± unpublished data).
sensitive erythroblastoma line, was used for reduction of back-
ground killing in the 51Cr release assay. Selection and HLA Typing of Naturally Exposed
Cell culture medium consisted of RPMI 1640 containing HEPES Study Populations
and L-glutamine (Life Technologies, Grand Island, NY) supple- Individuals were selected for study on the basis of presence of
mented with 2 mM L-glutamine (Irvine Scientific, Santa Ana, CA or selected HLA class I alleles. Subjects were aged between 15 and
Gibco, BRL Life Technologies, Grand Island, NY), 0.5 mM sodium 50 years, and informed consent was obtained in all cases.
pyruvate (Life Technologies), 100 U/100 mg/ml penicillin/streptomy- Caucasian volunteers were exposed to the bites of between 1008
cin (Irvine Scientific, Santa Ana, CA), and 5 or 10% heat-inactivated to 1576 (1.5 3 104 rad) g-irradiated Anopheles stephensi mosquitoes
human serum type AB (Gemini Bioproducts, Calabasas, CA, or ICN infected by membrane feeding with either the NF54 strain (Ponnu-
Biomedical, Costa Mesa, CA) or 10% heat-inactivated fetal calf se- durai et al., 1981) or the corresponding 3D7 clone (Walliker et al.,
rum (RPMI/10% FCS, Irvine Scientific, Santa Ana, CA). 1987) of P. falciparum, as previously described (Egan et al., 1993).
Subjects were exposed during 9±14 sessions over a period of 23
months.Affinity Purification of Class I HLA-A Molecules
and Peptide-Binding Assays Kenyan subjects were almost exclusively of the Luo ethnic group
and were residents of 1 of 15 contiguous villages in the AsemboCells were lysed at a concentration of 108 cells/ml in phosphate-
buffered saline containing 1% NP-40 and 1 mM phenylmethylsulfo- Bay area of Kenya, on the north and east shores of Lake Victoria.
In this area, the year-round prevalence of P. falciparum infectionnyl fluoride. The lysates were cleared of debris and nuclei by centrif-
ugation at 10,000 3 g for 20 min. MHC molecules were then purified among children 6 months to 6 years of age has been documented
as 94.4%±97.8% (Beier et al., 1994; McElroy et al., 1994; Beadle etby affinity chromatography as previously described (Sette et al.,
1994; Sidney et al., 1995). Inactivated Sepharose CL4B and protein al., 1995). A total of 197 Kenyans wereHLA typed using commercially
available serological typing plates (72-Ti-Black, One Lambda, Ca-A±Sepharose were used as precolumns.
Purified class I peptide-binding assays were performed as pre- noga Park, CA). HLA-A21 individuals were further subtyped using
an allele-specific polymerase chain reaction technique. Eighty-fiveviously described (Sette et al., 1994). In brief, purified human class
I molecules (5 to 500 nM) were incubated with 1±10 nM 125I-labeled individuals were selected for subsequent CTL and cytokine studies
(43 females and 42 males, mean age 27.8 years, range 16±48 years).probe peptide, iodinated by the chloramine T method (Buus et al.,
1987), for 48 hr at room temperature in the presence of 1 mM human Subjects reported an average of 2.1 episodes of clinical malaria
within the previous year. Parasitemia at the time of blood collectionb2-microglobulin (Scripps Laboratories, San Diego, CA) and a cock-
tail of protease inhibitors. Class I peptide complexeswere separated was assessed by examination of Giemsa-stained thick blood films,
and smears were considered negative after examination of 200 oil-from free peptide by gel filtration on TSK2000 columns, and the
fraction of bound peptide was calculated as previously described immersion fields. Sixteen of the 85 subjects were parasitemic (mean
parasitemia 4.5%). These donors were not excluded from analysis(Rebai and Malissen, 1983). In inhibition assays, peptide inhibitors
were typically tested at concentrations ranging from 120 mg/ml to because positive CTL responses were detected for 2 of the individu-
als, and positive cytokine responses for the majority. The human1.2 ng/ml. The data were then plotted and the dose yielding 50%
inhibition was measured. Because under these conditions [label] , immunodeficiency virus (HIV) infection status of individuals was as-
sessed using a commercially available kit designed to detect both[MHC] and IC50 > [MHC], the measured IC50sare reasonable approxi-
mations of the true KD values. HIV-1 and HIV-2 (Abbott Laboratories, Abbott Park, IL), according
Immunity
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to the manufacturer's specifications. Of the 85 subjects selected or with mitogen (PHA) were harvested and 50,000 cells aliquoted in
quadruplicate wells of 12-well slides. Slides were air-dried andfor CTL and cytokine studies, 26% tested positive for HIV-1 or HIV-2.
They were not excluded from the study because there was no asso- stored at 2708C prior to analysis. For each sampe analyzed, one
well was stained with fluorescein isothiocynate±-conjugated anti-ciated immunosuppression apparent with HIV infection.The average
mitogen response of HIV-infected individuals was equivalent to the CD31 (Becton Dickinson, San Jose, CA), anti-CD41 (Becton Dickin-
son) or anti-CD81 (Becton Dickinson) for 30 min at room tempera-response of uninfected individuals; peptide-specific cytokine re-
sponses were detected in all but one of the HIV-infected individuals; ture, or left unstained, washed three times with phosphate-buffered
saline, and mounted. Stained cells were quantitated visually usingand peptide-specific CTL responses were detected in two indi-
viduals. an Olympus microscope (Japan).
Induction and Assay of CTLs from Irradiated Statistical Analysis
Sporozoite±Immunized and Naturally The prevalence of dichotomous outcome variables (frequency of
Exposed Individuals peptide-specific CTL responses, proliferative T cell responses, or
In vitro induction of peptide-specific CTLs was achieved as de- cytokine responses) was assessed using the Pearson chi-square
scribed previously (Doolan et al., 1991; Sedegah et al., 1992), using test (two-tailed) and Fisher's exact test (two-tailed). Nonparametric
frozen PBMCs as effector cells. In brief, PBMCs were cultured at a continuous outcome variables (mean peptide-specific cytokine re-
concentration of 3±4 3 106 cells/2ml in 24-wellplates in the presence
sponse) were compared using the Mann-Whitney U rank sum test
of each MHC-matched peptide (10 mg/ml) or an MHC-mismatched
(two-tailed). Distributions of cytokine concentrations (log-trans-
peptide (10 mg/ml) for 7 days. Human rIL-2 (50 U/ml, Cetus) was
formed) did not deviate significantly from normality (data not shown).
added 2 days after the initiation of the culture. Cytolytic activity was
Bivariate correlations (associations between CTLs, cytokines, andassessed by conventional chromium release using autologous or
binding affinity), Pearson correlation coefficients and p values wereMHC-mismatched phytohemagglutinin P-activated lymphoblasts
calculated using the Pearson (two-tailed) and Spearman (two-tailed)(PHA blasts) as target cells. PHA blasts were generated by stimulat-
tests. Analysis was conducted using the SPSS statistical programing PBMCs with 0.2% (v/v, according to the manufacturer's specifi-
(SPSS, Chicago, IL).cations) PHA (Sigma, St. Louis, MO). Target cells were incubated
with or without peptide (10 mg/ml) and labeled with 100 mCi 51Cr
(sodium chromate solution, Dupont±NEN, Boston, MA) for 90 min, Acknowledgments
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